|
1.
|
|
17 p, 921.2 KB |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
/
Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ;
Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ;
Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ;
Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ;
Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ;
Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ;
Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ;
Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ;
Borin, Lorenza (Ospedale San Gerardo) ;
D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ;
Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ;
Voso, Maria Teresa (Tor Vergata University) ;
Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ;
Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ;
Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Nibourel, Olivier (Chu Lille) ;
Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ;
Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ;
Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ;
Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ;
Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ;
Santini, Valeria (University of Florence) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ;
Kern, Wolfgang (Mll Munich Leukemia Laboratory) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Haferlach, Torsten (Mll Munich Leukemia Laboratory) ;
Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 -  10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842
|
|
|
2.
|
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
|
3.
|
|
12 p, 801.4 KB |
The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
/
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. [...]
2023 - 10.3390/cancers15051483
Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483
|
|
|
4.
|
|
11 p, 1.2 MB |
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
/
Madariaga, Ainhoa (Universitat Autònoma de Barcelona) ;
Garg, Swati (University Health Network, Toronto, Canada) ;
Tchrakian, Nairi (University Health Network, Toronto, Canada) ;
Dhani, Neesha C. (University of Toronto, Canada) ;
Jimenez, Waldo (Juravinski Cancer Centre, Hamilton, Canada) ;
Welch, Stephen (London Health Sciences Center, London, Canada) ;
MacKay, Helen (Odette Cancer Centre. Sunnybrook Health Sciences Centre, Toronto, Canada) ;
Ethier, Josee-Lyne (Kingston Health Sciences Cancer Centre, Kingston, Canada) ;
Gilbert, Lucy (Royal Victoria Hospital, Montréal, Canada) ;
Li, Xuan (University Health Network, Toronto, Canada) ;
Rodriguez, Angela (University Health Network, Toronto, Canada) ;
Chan, Lucy (University Health Network, Toronto, Canada) ;
Bowering, Valerie (University Health Network, Toronto, Canada) ;
Clarke, Blaise (University Health Network, Toronto, Canada) ;
Zhang, Tong (University of Toronto, Canada) ;
King, Ian (University of Toronto, Canada) ;
Downs, Gregory (University of Toronto, Canada) ;
Stockley, Tracy (University of Toronto, Canada) ;
Wang, Lisa (University of Toronto, Toronto, Canada) ;
Udagani, Smitha (University Health Network, Toronto, Canada) ;
Oza, Amit M. (University of Toronto, Canada) ;
Lheureux, Stephanie (University of Toronto, Canada)
This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. [...]
2023 - 10.1038/s41467-023-37084-w
Nature communications, Vol. 14 (2023) , art. 1452
|
|
|
5.
|
|
11 p, 1.5 MB |
Intermittent androgen deprivation therapy : Recommendations to improve the management of patients with prostate cancer following the GRADE approach
/
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ;
Arevalo-Rodriguez, Ingrid (Hospital Ramon y Cajal (IRYCIS)) ;
Martínez García, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ;
Buitrago-Garcia, Diana (Universidad Tecnológica Equinoccial) ;
Lobos Urbina, D. (Pontificia Universidad Católica de Chile) ;
Cordero, José Antonio (Universitat Ramon Llull) ;
Universitat Autònoma de Barcelona
The purpose of this study was to provide evidence-based recommendations of intermittent androgen deprivation therapy (IADT) compared with continuous androgen deprivation therapy (CADT) for men with prostate cancer (PCA). [...]
2018 - 10.2147/CMAR.S164856
Cancer Management and Research, Vol. 10 (2018) , p. 2357-2367
|
|
|
6.
|
|
9 p, 203.7 KB |
Outcomes of men with HIV and germ cell cancer : Results from an international collaborative study
/
Hentrich, Marcus Ulrich (Department of Hematology and Oncology. Red Cross Hospital. University of Munich) ;
Bower, Mark (National Centre for HIV Malignancy. Chelsea and Westminster Hospital) ;
Daugaard, Gedske (Department of Oncology. University Hospital Copenhagen. Rigshospitalet) ;
Dieing, Annette (Department of Hematology and Oncology. Vivantes Klinikum am Urban) ;
Bickel, Markus (Infektiologikum) ;
Berretta, Massimiliano (Department of Clinical and Experimental Medicine. University of Messina) ;
Lesmeister, Florian (Department of Hematology and Oncology. Red Cross Hospital. University of Munich) ;
Jurinovic, Vindi (Institute of Biometrics and Epidemiology. Ludwig Maximilian University of Munich) ;
Stoehr, Albrecht (Institute for Interdisciplinary Medicine) ;
Heinzelbecker, Julia (Department of Urology and Pediatric Urology. Saarland University Medical Center and Saarland University) ;
Krznaric, Ivanka (Practice of Infectious Diseases) ;
Dieckmann, Klaus-Peter (Department of Urology. Asklepios Klinik Altona) ;
Necchi, Andrea (IRCCS San Raffaele Hospital and Scientific Institute. Vita-Salute San Raffaele University) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Rockstroh, Jürgen Kurt (Department of Medicine I. University Hospital Bonn) ;
Brito, Margarida (Instituto Português de Oncologia Francisco Gentil) ;
Pfister, David (Department of Urology. University Hospital Cologne) ;
Hoffmann, Christian (University Hospital of Schleswig Holstein)
Background: Previous studies have shown that men with HIV and germ cell cancer (HIV-GCC) have inferior overall survival (OS) in comparison with their HIV-negative counterparts. However, little information is available on treatments and outcomes of HIV-GCC in the era of combination antiretroviral therapy (cART). [...]
2022 - 10.1002/cncr.33928
Cancer, Vol. 128 Núm. 2 (January 2022) , p. 260-268
|
|
|
7.
|
|
17 p, 534.5 KB |
COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
/
Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Barlesi, Fabrice (Gustave Roussy) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Chu, Quincy (Cross Cancer Institute) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ;
Dakhil, Shaker (Cancer Center of Kansas) ;
Camidge, D (University of Colorado Anschutz Medical Campus) ;
Winzer, Leanne (AstraZeneca) ;
Soo-Hoo, Yee (AstraZeneca) ;
Cooper, Zachary A. (AstraZeneca) ;
Kumar, Rakesh (AstraZeneca) ;
Bothos, John (AstraZeneca) ;
Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227
|
|
|
8.
|
|
33 p, 2.0 MB |
Diagnosis and management of AML in adults : 2022 recommendations from an international expert panel on behalf of the ELN
/
Döhner, Hartmut (Ulm University Hospital. Department of Internal Medicine III) ;
Wei, Andrew H. (Peter MacCallum Cancer Centre. Royal Melbourne Hospital and University of Melbourne. Department of Haematology) ;
Appelbaum, Frederick (University of Washington. Fred Hutchinson Cancer Research Center) ;
Craddock, Charles (Centre for Clinical Haematology. Queen Elizabeth Hospital. University of Birminham) ;
DiNardo, Courtney D. (The University of Texas MD Anderson Cancer Center. Department of Leukemia) ;
Dombret, Hervé (Saint-Louis Institute for Research. Université de Paris. Hôpital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Department of Hematology) ;
Ebert, Benjamin L. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Fenaux, P. (Service d'Hématologie Séniors. Hôpital Saint-Louis. Assistance Publique-Hôpitaux de Paris) ;
Godley, Lucy A. (The University of Chicago. Section of Hematology/Oncology. Department of Medicine) ;
Hasserjian, Robert P (Massachusetts General Hospital) ;
Larson, Richard A (University of Chicago. Department of Medicine and Comprehensive Cancer Center) ;
Levine, Ross L. (Memorial Sloan Kettering Cancer Center. Human Oncology and Pathogenesis Program and Leukemia Service. Department of Medicine) ;
Miyazaki, Yasushi (Atomic Bomb Disease Institute. Nagasaki University. Department of Hematology) ;
Niederwieser, Dietger (University of Leipzig) ;
Ossenkoppele, Gert (Department of Haematology. Amsterdam UMC. Location VU University Medical Center) ;
Röllig, Christoph (Department of Internal Medicine I. University Hospital Carl Gustav Carus TU Dresden) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Stein, Eytan M. (Leukemia Service. Department of Medicine. Memorial Sloan Kettering Cancer Center) ;
Tallman, Martin S. (Leukemia Service. Department of Medicine. Memorial Sloan Kettering Cancer Center) ;
Tien, Hwei-Fang F. (Division of Hematology. Department of Internal Medicine. National Taiwan University Hospital) ;
Wang, Jianxiang (Institute of Hematology and Blood Diseases Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College) ;
Wierzbowska, Agnieszka (Department of Hematology. Medical University of Lodz) ;
Löwenberg, Bob (Department of Hematology. Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute)
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. [...]
2022 - 10.1182/blood.2022016867
Blood, Vol. 140 Núm. 12 (september 2022) , p. 1345-1377
|
|
|
9.
|
|
10 p, 306.4 KB |
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study
/
Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ;
Leleu, Xavier (CHU de Poitiers) ;
Touzeau, Cyrille (Université d'Angers) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paner, Agne (Rush University Medical Center) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Cavo, Michele (Bologna University School of Medicine) ;
Maisel, Christopher (Baylor Scott & White Charles A) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ;
Laubach, Jacob (Harvard Medical School) ;
Nadeem, Omar (Harvard Medical School) ;
Sandberg, Anna (Oncopeptides AB (Suècia)) ;
Orre, Marie (Oncopeptides AB (Suècia)) ;
Torrång, Anna (SDS Life Science (Suècia)) ;
Bakker, Nicolaas A (Oncopeptides AB) ;
Richardson, Paul G.. (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648
|
|
|
10.
|
|
14 p, 3.9 MB |
Combined analysis of miR-200 family and its significance for breast cancer
/
Fontana, Andrea (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Barbano, Raffaela (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Dama, Elisa (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Pasculli, Barbara (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Rendina, Michelina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Morritti, Maria Grazia (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Melocchi, Valentina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Castelvetere, Marina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Valori, Vanna Maria (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Ravaioli, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Bravaccini, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Ciuffreda, Luigi (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Graziano, Paolo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Maiello, Evaristo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Fazio, Vito Michele (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bianchi, Fabrizio (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Parrella, Paola (Fondazione IRCCS Casa Sollievo della Sofferenza)
While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a long follow-up (H-CSS cohort) and in TCGA-BRCA cohort. [...]
2021 - 10.1038/s41598-021-82286-1
Scientific reports, Vol. 11 Núm. 1 (december 2021) , p. 2980
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
